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Abstract
Introduction: Community-acquired pneumonia (CAP) requiring intensive care unit (ICU) treatment commonly
causes acute respiratory failure with high mortality. Kallistatin, an endogenous tissue kallikrein inhibitor, has been
reported to be protective in various human diseases. The aim of this study was to assess the correlations of
kallistatin with other biomarkers and to determine whether kallistatin levels have a prognostic value in severe CAP.
Methods: Plasma samples and clinical data were prospectively collected from 54 patients with severe CAP
requiring ICU admission. Seventeen healthy control subjects were included for comparison. Plasma kallistatin,
kallikrein, and other biomarkers of inflammation (tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, IL-6, IL-8,
C-reactive protein (CRP)), and anti-coagulation (protein C, anti-thrombin III) were measured on days 1 and 4 of ICU
admission. Comparison between survivors (n = 41) and nonsurvivors (n = 13) was performed.
Results: Plasma kallistatin was significantly consumed in severe CAP patients compared with healthy individuals.
Lower day 1 kallistatin levels showed a strong trend toward increased mortality (P = 0.018) and higher day 1 CURB-65
scores (P = 0.004). Plasma kallistatin levels on day 1 of ICU admission were significantly decreased in patients who
developed septic shock (P = 0.017) and who had acute respiratory distress syndrome (P = 0.044). In addition,
kallistatin levels were positively correlated with anti-thrombin III and protein C and inversely correlated with IL-1b,
IL-6, and CRP levels. In a multivariate logistic regression analysis, higher day 1 CURB-65 scores were independent
predictors of mortality (odds ratio = 29.9; P = 0.009). Also, higher day 1 kallistatin levels were independently
associated with a decreased risk of death (odds ratio, 0.1) with a nearly significant statistical difference (P = 0.056).
Furthermore, we found that a cutoff level of 6.5 μg/ml of day 1 kallistatin determined by receiver operating
characteristic curves could be used to distinguish between patients who survived in 60 days and those who did not.
Conclusions: These results suggest that kallistatin may serve as a novel marker for severe CAP prognosis and may
be involved in the pathogenesis of CAP through antiinflammatory and anticoagulation effects.
Introduction
Community-acquired pneumonia (CAP) is a common dis-
order that is potentially life threatening despite the advent
of potent antibiotics. Up to 36% of hospitalized CAP
patients require admission to the intensive care unit
(ICU). These patients present with more severe disease,
more morbidities, and higher mortality rate [1]. Thus out-
come evaluation is important for management of patients
with severe CAP requiring ICU admission. Practice guide-
lines based on severity-assessment tools, such as the
CURB-65 score, allow high-risk patients to be identified
and given specific treatment [2]. However, the prediction
rule is derived from clinical data and laboratorial para-
meters, which are more time-consuming and difficult to
obtain, thereby limiting the clinical applications of predic-
tive outcomes. Several biomarkers have been proposed to
assess illness severity and outcome. For example, inflam-
matory cytokines such as interleukin (IL)-6 [3] and
D-dimer [4] are associated with 30-day mortality and
major morbidity in patients with CAP. Procalcitonin [5-7],
albumin, and C-reactive protein (CRP) levels [8,9] have
also been shown to predict the severity of illness and
28-day mortality. However, most of these factors merely
reflect individual coagulation and inflammation status, but
have no therapeutic potential in themselves. Therefore,
identification of a new biomarker, capable not only of
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predicting outcomes but also of providing a potential
therapeutic target, would be more useful in clinical
applications.
Kallistatin, an endogenous human serine proteinase
inhibitor, was originally known as a tissue kallikrein
inhibitor. It binds strongly to tissue kallikrein and is
able to inhibit tissue kallikrein kininogenase and amido-
lytic activities in vitro [10,11]. However, kallistatin has
been reported to have various effects as an antiangio-
genic, antioxidant, antiapoptotic, and antiinflammatory
agent, independent of kallikrein inhibition [12-14]. A
significantly reduced kallistatin level was seen in plasma
samples from patients with liver disease and with sepsis,
suggesting that kallistatin is produced mostly in the liver
and can be consumed during sepsis. Its consumption in
sepsis may indicate a protective role to prevent blood
pressure reduction [10]. In an animal study, transgenic
mice overexpressing rat kallikrein-binding protein, shar-
ing a high degree of sequence identity with human kal-
listatin, were more resistant to LPS-induced lethality
[15]. Studies investigating adenovirus-mediated kallista-
tin gene therapy in rat models of collagen-induced
arthritis and osteoarthritis also showed that kallistatin
suppresses arthritis progression through its antiangio-
genesis, antiinflammation, and antiapoptosis activities
[16,17]. In addition, previous studies demonstrated that
kallistatin inhibits inflammatory cell infiltration and
oxidative stress in animal models of myocardial ische-
mia-reperfusion injury, myocardial infarction, and
salt-induced renal injury [13,14,18]. In the carbon tetra-
chloride-induced liver-injury mouse model, transgenic
expression of kallistatin was shown to attenuate liver
damage through reduction of oxidative stress [19].
These findings indicate that kallistatin has protective
effects against vascular and organ damage by preventing
inflammation, apoptosis, and oxidative stress. Given that
kallistatin can be found in a wide range of human tis-
sues and fluids, including kidney, lung, myocardium,
blood vessels, plasma, and urine [10,20], its plasma
levels might be relevant to infectious diseases, which
commonly induce multiple organ dysfunction and lead
to death. To our knowledge, clinical studies investigating
the association of plasma kallistatin levels with human
infectious diseases, such as CAP, are still lacking.
In this study, we hypothesized that kallistatin may be
involved in regulation of the processes of inflammation
and coagulation in severe CAP and may be associated
with the outcome. Therefore, we sought to determine
the correlations of plasma kallistatin with other bio-
markers, including factors of anticoagulation (protein
C, anti-thrombin III) and inflammation (tumor necro-
sis factor (TNF)-a, IL-1b, IL-6, IL-8, CRP), and to




In a prospective observational study, we consecutively
enrolled patients who were admitted to our medical ICU
because of severe CAP in National Cheng Kung University
Hospital, a tertiary referral center in southern Taiwan,
between April 2010 and January 2011. Study approval was
obtained from the Institutional Review Board of the
National Cheng Kung University Hospital. Written
informed consent was obtained from all participants or
their legal representatives if the patients were unconscious.
Adult patients with pneumonia that required ICU admis-
sion were initially screened for severe CAP. Exclusion
criteria were pregnancy, human immunodeficiency virus
infection, immunosuppressive treatment, and tuberculosis.
Pneumonia was diagnosed if patients presented with acute
lower respiratory tract infection, new or progressive pul-
monary infiltrates on chest radiography, and identification
of microbes in the lower respiratory tract. Severe CAP was
defined according to the American Thoracic Society
(ATS) criteria [21]. Exclusion criteria were refusal of
informed consent, prior hospitalization within 15 days
before admission, pneumonia developing during hospitali-
zation, terminal illness receiving palliative treatment, and
delayed ICU admission for more than 48 hours. All
patients were initially treated with broad-spectrum anti-
biotics, based on the ATS guideline, as early as possible
[21]. Subsequent adjustments of the antimicrobial regimen
were based on the antibiotic susceptibilities and the opi-
nions of infectious specialists once causative pathogens
were defined. Clinical response of antimicrobial therapies
was evaluated daily, and treatments and cultures were
reassessed and reexamined in patients who showed a dete-
riorated condition.
We also studied 17 healthy subjects for comparison
analyses.
Study design and definitions
Demographic data (age, gender, comorbidities), complica-
tions (septic shock at ICU admission, development of
ARDS, need for mechanical ventilation), clinical variables
(blood pressure, body temperature, respiratory rate, heart
rate), laboratory data (arterial blood gas, blood cell count,
biochemical data), and outcome data (length of ICU and
hospital stay, duration of mechanical ventilation, hospital
mortality) were collected. The worst daily values for all
variables of interest were recorded to calculate the Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score [22] on day 1 and Sequential Organ Failure
Assessment (SOFA) score [23] on days 1 and 4 of ICU
admission. Severe CAP was diagnosed according to ATS
criteria, and its severity was evaluated by using the CURB-
65 score, an acronym for each of the risk factors mea-
sured, including confusion of new onset (defined as an
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abbreviated mental test score of 8 or less), urea greater
than 7 mM (19 mg/dl), respiratory rate of 30 breaths per
minute or greater, blood pressure less than 90 mm Hg sys-
tolic or diastolic blood pressure 60 mm Hg or less, and age
65 years or older [21]. Patients were followed up until
death or 60 days after ICU admission for outcome.
Plasma biomarker measurements
Blood samples were collected on days 1 and 4 of ICU
admission in heparinized tubes and centrifuged for
10 minutes at 3,000 g. Then plasma aliquots were stored
at -80°C until the time of analysis. Levels of kallistatin,
kallikrein, and the inflammatory biomarkers, including
TNF-a, IL-1b, IL-6, and IL-8, were determined in dupli-
cate by using enzyme-linked immunosorbent assay kits
(R&D Systems, Minneapolis, MN, USA). Anticoagula-
tion factors protein C and antithrombin III were also
measured by using chromogenic assay kits (Instrumenta-
tion Laboratory, Bedford, MA, USA), and CRP by using
an immunoturbidimetric method with a commercially
available test (Beckman Coulter, Fullerton, CA, USA).
Statistical analysis
All statistical analyses were performed by using a statis-
tical software package (PASW for Windows, version
18.0; SPSS Inc, Chicago, IL, USA). Continuous variables
were expressed as median (range). Differences of contin-
uous variables between groups were compared by using
the Mann-Whitney U test, and those of categoric vari-
ables were compared with the c2 test. The Kruskal-
Wallis test was used to compare variables among more
than three groups. Levels of significance were expressed
as P values. Multivariate logistic regression analysis was
performed to analyze the independent risk factors for
hospital mortality. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) were calculated according to the
higher value of each variable, except for gender. The
median values were used to discriminate between the
high and low groups. For the variable gender, male gen-
der was used. Initially, the biomarker variables (kallista-
tin, kallikrein, protein C, antithrombin III, TNF-a, IL-
1b, IL-6, IL-8, CRP) and disease-severity scores (CURB-
65 score, SOFA score, APACHE II score) on day 1 of
ICU admission were analyzed by using univariate analy-
sis. The variables that showed significant or nearly sig-
nificant differences (that is, P < 0.2) on univariate
analysis were then entered in a multivariate logistic
regression model to derive the independent prognostic
factors. Spearman correlation-of-rank coefficient was
used to analyze correlations between kallistatin and
other biomarkers. Furthermore, the areas under the
receiver operating characteristic (ROC) curve and
Kaplan-Meier curve were drawn for kallistatin to evalu-
ate the ability to discriminate between patients who
survived and those who died. The optimal kallistatin
cutoff was defined as the value associated with the high-
est sum of sensitivity and specificity (Youden index).
Differences between the Kaplan-Meier curves were
assessed by using the log-rank test. A two-sided P value
≤ 0.05 was considered to be statistically significant.
Results
Demographic and clinical characteristics of severe CAP
patients
In total, 135 patients admitted to ICUs with a diagnosis
of pneumonia were screened during the enrollment period,
and 13 patients were screened with a refusal of informed
consent, 27 with prior hospitalization within 15 days before
admission, 28 with an underlying terminal illness receiving
palliative treatment, and 13 with delayed ICU admission
more than 48 hours were excluded, leaving 54 patients
with severe CAP included in this study. The demographic
data and clinical variables are summarized in Table 1.
Table 1 Comparisons between survivors and






Age, year 76 (21-93) 77 (33-96) 0.142
Gender, male, n (%) 27 (66) 7 (54) 0.652
Comorbidities, n (%)
Diabetes 8 (20) 2 (15) 1.000
Chronic kidney disease 4 (10) 1 (8) 1.000
Chronic respiratory disease 7 (17) 2 (15) 1.000
Liver cirrhosis 2 (5) 1 (8) 1.000
Malignancy 5 (12) 1 (8) 1.000
ARDS, n (%) 7 (17) 7 (54) 0.025a
Invasive mechanical ventilation,
n (%)
33 (80) 13 (100) 0.176
Septic shock at ICU admission,
n (%)
20 (49) 11 (85) 0.051b
Positive blood cultures, n (%) 7 (17) 4 (31) 0.285
APACHE II score, points 18 (6-36) 25 (14-40) 0.027a
SOFA score, points
Day 1 6 (0-15) 14 (3-18) 0.018a
Day 4 5 (0-18) 8.5 (2-17) 0.045a
CURB-65 score, points
Day 1 3 (2-5) 4 (3-5) 0.002a
Day 4 3 (0-5) 4 (1-5) 0.021a
ICU stay, days 9 (3-64) 13 (2-47) 0.277
Hospital stay, days 20 (9-64) 18 (2-52) 0.302
Mechanical ventilation, days 8 (0-67) 13 (2-48) 0.247
Data are presented as median (range), unless stated otherwise. APACHE II,
Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory
distress syndrome; CURB-65, confusion of new onset (defined as an
abbreviated mental test score of 8 or less), urea >7 mM (19 mg/dl), respiratory
rate of 30 breaths per minute or greater, blood pressure <90 mm Hg systolic
or diastolic blood pressure 60 mm Hg or less, and age 65 years or older; ICU,
intensive care unit; SOFA, Sequential Organ Failure Assessment. aStatistically
significant. bNearly statistically significant.
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Forty-six (85%) patients required invasive mechanical
ventilation on ICU admission. The overall hospital mortal-
ity in the cohort was 24.1%. Survivors and nonsurvivors
were similar in terms of age, gender, comorbidities, the
need for invasive mechanical ventilation, positive blood
cultures, the length of ICU and hospital stay, and the
duration of mechanical ventilation. More patients had
acute respiratory distress syndrome (ARDS) (P = 0.025)
and with septic shock at ICU admission (P = 0.051) in the
group that did not survive. Markers of disease severity,
including APACHE II, SOFA, and CURB-65 scores, were
significantly higher in nonsurvivors compared with
survivors.
Comparison of kallistatin and other biomarkers between
the groups
We found that kallistatin was significantly consumed in
CAP patients compared with healthy subjects, but no
significant differences in kallikrein levels were observed
between the two groups (Table 2). The comparison of
plasma biomarker levels between survivors and nonsur-
vivors is shown in Table 3. Lower day 1 and 4 levels of
kallistatin (P = 0.049 and P = 0.002, respectively) and
antithrombin III (P = 0.037 and P = 0.004, respectively)
and day 4 of protein C (P = 0.013) were found in
patients who died compared with those who survived,
indicating greater consumption of these factors in the
group of patients who died. Nevertheless, inflammatory
biomarkers, IL-8 levels on days 1 and 4 (P = 0.005 and
P = 0.003, respectively), and IL-6 on day 4 (P = 0.052),
were higher in nonsurvivors compared with survivors.
No significant differences were noted in the levels of
kallikrein, TNF-a, IL-1 b, and CRP between survivors
and nonsurvivors. In addition, we further examined the
associations of kallistatin with the development of com-
plications, and found that day 1 kallistatin plasma levels
were significantly lower in patients who had septic
shock and developed ARDS than those who did not
(P = 0.017 and P = 0.044, respectively) (Figure 1).
Univariate and multivariate analysis of baseline severity
scores and biomarkers
We divided each variable into the high and low groups
by using the median values, except for the variable gen-
der. ORs and 95% CIs were calculated according to the
higher value of each variable, except for gender, for
which male was used. In univariate analysis, day 1
plasma kallistatin (OR = 0.21; 95% CI = 0.05 to 0.89;
P = 0.034), IL-8 (OR = 4.71; 95% CI = 1.12 to 19.70; P =
0.034), CURB-65 (OR = 8.06; 95% CI = 1.88 to 34.52;
P = 0.005), and SOFA scores (OR = 4.71; 95% CI = 1.12
to 19.70; P = 0.034) were significantly associated with
death (Table 4). In multivariate models, apart from
CURB-65 score as an independent predictor (OR =
29.85; 95% CI = 2.36 to 378.25; P = 0.009), the kallistatin
levels tended to be associated with death among the
other tested factors, with P < 0.2 in univariate analysis
(OR = 0.11; 95% CI = 0.01 to 1.06; P = 0.056) (Table 4).
Table 2 Comparison of plasma kallistatin and kallikrein
levels between patients with severe community-acquired






Day 1 Day 4
Kallistatin (μg/ml) 17.2 (5.3-82.7) 8.3 (1.3-17.3)a 11.0 (1.8-18.3)b






Data are presented as median (range). aDay 1 plasma kallistatin levels of
patients were compared with those of normal subjects; P < 0.001. bDay 4
plasma kallistatin levels of patients were compared with those of normal
subjects; P < 0.001.
Table 3 Comparisons of plasma biomarkers between








Day 1 8.7 (3.0-17.3) 6.5 (1.3-16.2) 0.049a
Day 4 11.7 (2.1-18.3) 7.3 (1.8-11.3) 0.002a
Kallikrein (pg/ml)
Day 1 216.6 (29.9-4,459.9) 172.0 (16.5-4,085.0) 0.436
Day 4 169.9 (8.6-3,103.1) 126.8 (50.4-3,307.4) 0.738
Protein C (%)
Day 1 57.6 (11.3-104.0) 58.0 (19.4-251.4) 0.485
Day 4 76.0 (18.9-126.6) 54.7 (15.5-78.0) 0.013a
Antithrombin III (%)
Day 1 76.0 (30.8-122.6) 62.5 (22.1-86.2) 0.037a
Day 4 84.0 (34.4-112.6) 60.8 (27.0-87.2) 0.004a
TNF-a (pg/ml)
Day 1 4.2 (0.7-497.1) 7.7 (1.1-249.2) 0.307
Day 4 9.1 (1.2-395.9) 20.4 (2.0-2,630.8) 0.100
IL-1b (pg/ml)
Day 1 0.6 (0.0-5.5) 0.8 (0.1-12.1) 0.390
Day 4 0.7 (0.0-14.1) 1.1 (0.5-2.3) 0.127
IL-6 (pg/ml)
Day 1 78.1 (5.5-600.0) 197.7 (7.4-600.0) 0.108
Day 4 53.0 (3.2-257.6) 181.2 (17.3-600.0) 0.052
IL-8 (pg/ml)
Day 1 25.2(2.4-592.0) 69.7 (18.3-4,000.0) 0.005b
Day 4 18.0 (2.5-160.5) 60.4 (20.8-907.0) 0.003b
CRP (μg/ml)
Day 1 124.9 (9.7-433.0) 113.9 (42.9-339.5) 0.833
Day 4 57.6 (7.0-229.5) 127.6 (21.7-313.4) 0.148
Data are expressed as median (range). CRP, C-reactive protein; IL, interleukin;
TNF-a, tumor necrosis factor-a. aSignificantly lower in nonsurvivors.
bSignificantly higher in nonsurvivors.
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Furthermore, we summarized the observed mortality by
quartile of day 1 kallistatin levels. In comparison with the
overall mortality of 24.1%, a categoric increase in death
was observed from 8% in the lowest quartile to 43% in
the highest quartile, with a significant test for trend
across quartiles (P = 0.018) (Figure 2A). On further analy-
sis of the association between day 1 kallistatin levels and
severity of illness, we found a categoric decrease in kallis-
tatin levels with a significant trend test across three cate-
gories of CURB-65 score (P = 0.004) (Figure 2B). In
addition, to determine the optimal cutoff values of day 1
plasma kallistatin for mortality, ROC curves were also
constructed with an area under the curve of 0.683 (P =
0.048) (Figure 3A). Optimum cutoff value of 6.5 μg/ml
was obtained with the sensitivity of 81% and specificity of
54% (Figure 3A). In accordance with the cut-off value
determined by the ROC curves for mortality, the 60-day
survival rate was further evaluated by Kaplan-Meier ana-
lysis. All patients who did not survive in 60-day follow-up
were shown to die during hospitalization, and their death
was related to severe CAP, based on the medical records.
Survival rate in patients with high levels of plasma kallis-
tatin was significantly higher than in groups with low
levels (Figure 3B; see also Additional file 1, Figure S1 for
a large illustration).
Relation between plasma kallistatin and other biomarkers
in severe CAP
Given the fact that both inflammation and coagulation
have a predictive role in the severity and outcome of CAP
[3,9,24,25], we further determined the association between



































Figure 1 Relation between plasma kallistatin levels on days 1 and 4 of intensive care unit (ICU) admission and the development of
septic shock and acute respiratory distress syndrome (ARDS) in severe community-acquired pneumonia (CAP) patients. Comparison of
days 1 and 4 plasma kallistatin levels between patients with and without the development of septic shock (A) and of ARDS (B). Mann-Whitney
nonparametric test was used for comparisons between the groups.
Table 4 Univariate and multivariate analysis for
predicting mortality in patients with severe community-
acquired pneumonia
Variables P value OR 95% CI
Univariate analysis
Age >76 years 0.436 1.647 0.470-5.778
Gender (male) 0.437 0.605 0.170-2.148
Kallistatin >8.3 μg/ml 0.034a 0.213 0.051-0.890
Kallikrein >203.4 pg/ml 0.343 1.853 0.518-6.629
Protein C >57.6% 0.991 1.008 0.288-3.521
Antithrombin III >72.9% 0.170 0.386 0.099-1.501
TNF-a >4.2 pg/ml 0.869 1.111 0.318-3.881
IL-1b >0.6 pg/ml 0.343 1.853 0.518-6.629
IL-6 >90.2 pg/ml 0.343 1.853 0.518-6.629
IL-8 >33.4 pg/ml 0.034a 4.706 1.124-19.704
CRP >129.5 μg/ml 0.750 0.816 0.234-2.851
CURB-65 score >3 0.005a 8.056 1.880-34.516
SOFA score >6 0.034a 4.706 1.124-19.704
APACHE II score >19 0.161 2.500 0.694-9.005
Multivariate analysis
Kallistatin >8.3 μg/ml 0.056b 0.114 0.012-1.058
Antithrombin III >72.9% 0.457 2.262 0.264-19.390
IL-8 (pg/ml) >33.4 pg/ml 0.130 6.854 0.568-82.733
CURB-65 score >3 0.009b 29.850 2.356-378.246
SOFA score >6 0.589 1.760 0.226-13.684
APACHE II score >19 0.182 0.213 0.0220-2.067
APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence
interval; CRP, C-reactive protein; CURB-65, confusion of new onset (defined as
an abbreviated mental test score of 8 or less), urea >7 mM (19 mg/dl),
respiratory rate of 30 breaths per minute or greater, blood pressure <90 mm
Hg systolic or diastolic blood pressure 60 mm Hg or less, and age 65 years or
older; IL, interleukin; OR, odds ratio; TNF-a, tumor necrosis factor-a.
aStatistically significant in univariate analysis. bStatistically nearly significant or
significant in multivariate analysis.
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factors. We found that day 1 kallistatin was negatively
correlated with day 1 CRP (r = -0.469; P = 0.0003)
(Figure 4A), but positively correlated with day 1 antithrom-
bin III (r = 0.475; P = 0.0004) (Figure 4B). Furthermore,
day 4 kallistatin was shown to be negatively correlated with
day 4 IL-1b (r = -0.427; P = 0.004) and IL-6 (r = -0.510;
P = 0.0005) (Figure 4C, D), but positively correlated with
day 4 antithrombin III (r = 0.489; P = 0.0007) and protein
C (r = 0.511; P = 0.0004) (Figure 4E, F).
Discussion
This study demonstrates that plasma kallistatin is con-
sumed in patients with severe CAP requiring ICU
admission as compared with healthy individuals, and its
levels are associated with disease severity and outcome.
The hospital mortality rate of 24% in this study is con-
sistent with that reported in other studies [9]. We
showed that lower levels of kallistatin have a strong
trend toward predicting worse clinical outcomes, accom-
panied by increased systemic coagulation and inflamma-
tion. We also found that kallistatin correlated positively
with anticoagulation factors (protein C and antithrom-
bin III) and negatively with inflammatory factors (CRP,
IL-1b, and IL-6), suggesting that both anticoagulation
and antiinflammation events may contribute to these
physiological and outcome benefits. To our knowledge,
this is the first study to demonstrate the role of kallista-
tin in severe CAP.
Kallistatin is known to play an important role in pre-
vention of various diseases, including cancer, cardiovas-
cular diseases, and arthritis, through the effects of
antiangiogenic, antiinflammatory, antiapoptotic and anti-
oxidative processes [12,13,16,18]. A prior study of kallis-
tatin in human sepsis showed significantly reduced
plasma kallistatin levels in patients with sepsis compared
with healthy individuals, suggesting a protective role of
kallistatin in sepsis through regulation of inflammatory
processes [10]. In a murine model of endotoxic shock,
transgenic mice overexpressing the rat kallikrein-binding
protein gene, a functional analogue of kallistatin, were
shown to have a higher survival rate than nontransgenic
control mice [15]. Our study demonstrated similar
results with decreased plasma kallistatin levels at days 1
and 4 of ICU admission in severe CAP patients com-
pared with healthy individuals. Kallikrein is a compo-
nent of the kallikrein/kinin system, which is known to
regulate hemostatic and inflammatory processes and can
be consumed during sepsis [26]. However, we found
that plasma kallikrein levels were not significantly differ-
ent between CAP patients and healthy individuals. The
discrepancy may be related to the differences in studied
populations or reflect the relatively small sample size.
Of note, no correlations were found between kallistatin
and kallikrein in our study, suggesting that the effects of
kallistatin were independent of the kallikrein/kinin sys-
tem. In addition, lower plasma kallistatin levels were
found in patients affected with septic shock and ARDS,
suggesting the protective effects of kallistatin against
such complications.
In agreement with other reports in different popula-
tions, severity-score systems showed an association with
mortality in CAP [3,7,27]. As expected, the SOFA and
CURB-65 were associated with hospital mortality. In
keeping with prior studies [3,24,28,29], we demonstrated
that IL-8 levels were higher in nonsurvivors, whereas
protein C and antithrombin III levels were lower in
patients who died. These findings indicate that greater
upregulation of the acute inflammatory process and acti-
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Figure 2 Plasma kallistatin levels on day 1 of intensive care
unit (ICU) admission are associated with the mortality and
severity of community-acquired pneumonia (CAP). (A) Observed
mortality according to quartile of day 1 plasma kallistatin levels. Test
for trend across quartile was performed. (B) Plasma kallistatin levels
on day 1 of ICU admission according to day 1 CURB-65 score in
tertiles. Test for trend across tertiles was performed.
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vation of coagulation pathways occurred in patients with
severe CAP who did not survive their illness. We also
showed lower kallistatin levels in the nonsurvivors than
in the survivors. However, kallikrein levels did not differ
between the two groups, implying that the potential
effects of kallistatin on the outcomes of CAP are not
related to the interaction with kallikrein.
In multivariate analysis for biomarkers and severity
scores, CURB-65 was shown to be an independent pre-
dictor for mortality in keeping with other reports
[3,7,27]. Although we found only a nearly statistical sig-
nificance in kallistatin to predict mortality indepen-
dently, we indeed demonstrated that decreased plasma
kallistatin levels have a strong trend toward increased
mortality and severity. These findings were also con-
firmed by a Kaplan-Meier survival-curve analysis, which
revealed a better survival rate in patients with high kal-
listatin levels than in those with low levels.
We observed that lower kallistatin was associated with
a reduced anticoagulation, shown by decreased levels of
antithrombin III and protein C, but associated with
increased inflammation, demonstrated by elevated levels
of IL-1b, IL-1, and CRP. These findings are supported
by other studies that showed markedly lower circulating
kallistatin levels in humans with sepsis [10] and with
necrotic acute pancreatitis [30], in which the inflamma-
tory response is enhanced, and the anticoagulant
response is suppressed [29]. In animal studies, kallistatin
gene delivery inhibited inflammation in a rat renal dis-
ease model [14], acute myocardial ischemia-reperfusion
injury [13], and a rat arthritis model [16], indicating that
kallistatin is relevant to an antiinflammatory effect. To
the best of our knowledge, no reports illustrate the rela-
tion between kallistatin and anticoagulant factors.
Although it is well known that the kallikrein/kinin sys-
tem is involved in regulation of hemostasis via activation
of the intrinsic pathway of coagulation, leading to the
formation of a fibrin network, the role of this system in
induction of pathologic coagulation disorders in severe
infectious diseases is still controversial [26]. Another
possible reason is that declining circulating antithrom-
bin III and protein C levels caused by increased con-
sumption during illness may simply be a marker for
greater severity of illness, as were lower kallistatin levels.
A strength of this study was the concurrent measure-
ment of other biomarkers, including inflammation and
anticoagulant factors involved in the pathogenesis of
CAP, and evaluated the relations between kallistatin and
these molecules. The major limitations of our study
include its small sample size in a single medical center,
which may account for some lack of statistical signifi-
cance. The small patient population also prevented a sub-
group analysis to examine further the differences in the
effects of kallistatin on clinical outcomes according to
some comorbidities. However, the distribution pattern of
comorbidities between survivors and nonsurvivors was
similar in our cohort. Furthermore, we cannot exclude
the possibility that different therapeutic interventions
may affect the results through unknown interactions with
kallistatin. Future studies using more subjects are
required to substantiate our findings further and to con-
firm the potential benefits of kallistatin in severe CAP.
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Figure 3 Plasma kallistatin levels on day 1 of intensive care unit (ICU) admission and likelihood of 60-day survival. (A) Receiver
operating characteristic curves determining the cutoff value of day 1 kallistatin (6.5 μg/ml) to discriminate between survivors and nonsurvivors.
(B) Kaplan-Meier curves of 60-day survival with patients grouped according to day 1 kallistatin levels >6.5 μg/ml or <6.5 μg/ml at ICU admission.
Log-rank test was performed for comparisons between the groups. AUC, area under the curve.
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Figure 4 Correlation between plasma kallistatin levels and other biomarkers in patients with severe community-acquired pneumonia
(CAP). Correlations between plasma kallistatin levels on day 1 of intensive care unit (ICU) admission and day 1 plasma levels of C-reactive
protein (CRP) (A) and antithrombin III (B) are shown. The correlations between plasma kallistatin levels on day 4 of ICU admission and day 4
plasma levels of IL-1b (C), IL-6 (D), anti-thrombin III (E), and protein C (F) also are shown. Nonparametric Spearman rank-correlation coefficient
was used to test correlations between two biomarkers.
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Conclusions
In this study, we demonstrated that lower levels of kallis-
tatin are associated with more-severe illness and
increased mortality. In addition, kallistatin levels were
positively correlated with the levels of anticoagulation
factors (antithrombin III and protein C) and inversely
correlated with the levels of inflammatory mediators (IL-
1b, IL-6, and CRP). These findings indicate that kallista-
tin may be protective against severe CAP, which implies
possible therapeutic benefits of kallistatin in these
patients. Follow-up animal studies would be useful to
confirm our observations.
Key messages
• Plasma kallistatin was consumed more in patients
with severe community-acquired pneumonia (CAP)
than in healthy individuals.
• Lower plasma kallistatin levels on day 1 of ICU
admission were correlated with increased in-hospital
and 60-day mortality and elevated day 1 CURB-65
scores in patients with severe CAP.
• Lower day 1 plasma kallistatin levels were asso-
ciated with the development of septic shock and
acute respiratory distress syndrome in patients with
severe CAP.
• Plasma kallistatin levels were positively correlated
with the levels of antithrombin III and protein C and
negatively correlated with the levels of IL-1b, IL-6,
and CRP.
• The results indicate that plasma kallistatin was
associated with the outcomes of severe CAP, which
may be related to antiinflammatory and anticoagula-
tive effects.
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